Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more

Recent & Breaking News (NDAQ:IMUX)

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

PR Newswire June 15, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

PR Newswire June 8, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

PR Newswire June 2, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 10, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

PR Newswire May 5, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

PR Newswire May 3, 2022

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

PR Newswire April 25, 2022

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

PR Newswire March 16, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in March

PR Newswire March 8, 2022

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

PR Newswire February 24, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

PR Newswire February 18, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

PR Newswire February 17, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in February

PR Newswire February 8, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

PR Newswire February 2, 2022

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

PR Newswire December 14, 2021

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

PR Newswire December 9, 2021

Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference

PR Newswire November 23, 2021

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

PR Newswire November 18, 2021

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

PR Newswire November 4, 2021

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update

PR Newswire November 1, 2021